Lonvo-z: hereditary-angioedema FDA decision
HAELO met its primary endpoint in April 2026; that trial-success question is already answered. The pending next catalyst is the FDA BLA review of lonvoguran ziclumeran (lonvo-z), with priority review and a March 10, 2027 target confirmed in the September acceptance filing.
Intellia Therapeutics / NTLADrug catalystsRegulatory decisionTarget: 2027-03-10
What matters
Follow the exact application, indication and requested label. An FDA decision concerns the drug program, while the company’s stock also reflects its other assets and business.
Primary evidence
FDA target 2027-03-10 — not a guaranteed decision date
Intellia · lonvo-z BLA acceptance / PDUFAPublished 2026-09-08
Intellia · HAELO result already disclosedPublished 2026-04-27
Potential outcome market
Will FDA approve lonvoguran ziclumeran for hereditary angioedema by a separately fixed evidence cutoff?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.